1 / 7

No generics without originals or do we need innovation at all?

No generics without originals or do we need innovation at all?. Robert Gal MD. R&D process of a new compound. Time to market is 15 years without the reimbursement obtained patent is 10-15 years from the 1 st registration in the world Registration timelines in Serbia?

carlow
Télécharger la présentation

No generics without originals or do we need innovation at all?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. No generics without originals or do we need innovation at all? Robert Gal MD

  2. R&D process of a new compound • Time to market is 15 years without the reimbursement obtained • patent is 10-15 years from the 1st registration in the world • Registration timelines in Serbia? • Market access with reimbursement in Serbia? • How many years is left to an original molecule in Serbia? No of compounds in the process

  3. R&D spending of the industry

  4. Generic – original shares in different European countries

  5. Serbian market is quite advanced regarding generic penetration • Due to the very low price level spending on generics is already higher

  6. Increasing disease prevalence Diabetes Movement disorders CNS Costs are driven by the disease prevalence ! - Oncology still will drive the costs • Life expectancy is increasing • The number of years spent without a disease is NOT!

  7. The structure of RZZO expenditures – based on IMS sales and reimbursement levels • What is the strategy behind the expenditures? • What are the priority therapy areas? • What are the rationalities behind level of reimbursements?

More Related